Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Cowden

Pulmonary Disease Longmont, CO Medical Doctor

NPI 1982665071 CMS profile 45103

1750 E Ken Pratt Blvd, Longmont, CO 80504

Open in the dashboard

General payments

$6,721

70 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$54,998 paid to institutions, not to them · program year 2021

Through program year 2025, John Cowden of Longmont, CO is reported in the CMS Open Payments database as having received $6,721 across 70 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $54,998 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 72nd percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,388 12
2024 General $1,040 11
2023 General $980 13
2022 General $1,734 13
2021 General $29 5
2020 General $393 10
2019 General $156 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Cowden
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to John Cowden were reported at $2,388. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year John Cowden Pulmonary Disease median Middle half National median
2019 $156 $377 $109–$1,340 $163
2020 $393 $230 $56–$907 $114
2021 $29 $269 $68–$1,072 $132
2022 $1,734 $390 $100–$1,457 $149
2023 $980 $419 $114–$1,659 $160
2024 $1,040 $476 $123–$1,818 $164
2025 $2,388 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $5,547 39 payments
  2. Pulmonx Corporation $249 3 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $236 3 payments
  4. United Therapeutics Corporation $156 7 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $139 2 payments
  6. Merck Sharp & Dohme Corporation $112 3 payments
  7. Boston Scientific Corporation $70 1 payment
  8. Mylan Specialty L.P. $64 3 payments
  9. Novartis Pharmaceuticals Corporation $35 2 payments
  10. Actelion Pharmaceuticals US, Inc. $27 1 payment
  11. Other $86 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $3,727 20 payments
  2. Food and Beverage $2,227 41 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $500 1 payment
  4. Education $267 8 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $5,547 39 payments
  2. Adempas $139 2 payments
  3. Pulmonx Endobronchial Valve EBV $136 2 payments
  4. OFEV $114 1 payment
  5. CHARTIS CATHETER $113 1 payment
  6. ZEPHYR DELIVERY CATHETER $113 1 payment
  7. ZEPHYR ENDOBRONCHIAL VALVE $113 1 payment
  8. PULMONX CHARTIS TABLET CONSOLE $113 1 payment
  9. WINREVAIR $101 2 payments
  10. ACQUIRE $70 1 payment
  11. Other $446 27 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,162

Median for Pulmonary Disease: 936

Drug cost

$665,600

Median for Pulmonary Disease: $487,987

Branded share of claims

60.3%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 30 $381,889
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 131 $103,431
Spiriva Respimat Tiotropium Bromide Brand 91 $52,344
Spiriva Handihaler Tiotropium Bromide Brand 28 $24,771
Eliquis Apixaban Brand 20 $17,226
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 80 $16,619
Sildenafil Citrate Generic 36 $11,995
Symbicort Budesonide/Formoterol Fumarate Brand 27 $9,356
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 13 $8,572
Breo Ellipta Fluticasone/Vilanterol Brand 11 $7,110

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$83,359

Medicare's payments for the services billed

Medicare patients

289

Average age 74

Services billed

887

164 women, 125 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
COPD 59%
Ischemic heart disease 53%
Heart failure 42%
Arthritis 41%
Cancer 32%
Diabetes 29%
Chronic kidney disease 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $114
$114 30 —
WINREVAIR
  • Merck Sharp & Dohme Corporation $101
$101 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

70 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record